Key facts
- It has raised $3.2M; the latest was Grant ($2.9M) in Sep 2025.
- Notable investors include European Union, INNVIERTE SICC, Inveready Asset Management, CDTI Innvierte, David Prous — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CONNECTA Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for CONNECTA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CONNECTA Therapeutics
Operator of a biotechnology company intended to develop new treatments for central nervous system disorders. The company researches and develops molecules for neuroplasticity-mediated disorders with social behavior and pro-cognitive properties, enabling healthcare and medical professionals to provide treatment for X syndrome to patients.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2019
- Employees
- 7
- Website
- connectatherapeutics.com/
- Ownership
- Privately Held (backing)
CONNECTA Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CONNECTA Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CONNECTA Therapeutics in its N-PORT filings yet. We sweep new filings monthly.